4 completed, 2 terminated, 1 unknown. 4 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 4 | Terminated 2, Completed 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow valrubicin: new trials by email Literature Review of valrubicin trials Research Report on valrubicin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer CG0070 Adenovirus Vector, Control Arm: Quadruple Choice - Transitional Cell Carcinoma, Bladder Cancer | Phase 2 / Phase 3 | Terminated | CG Oncology, Inc. | 22 | 2014-03-01 | 2021-04-14 |
| Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma Valrubicin - Urothelial Carcinoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 4 | 2012-07-01 | 2016-04-22 |
| Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder VALSTAR - Maintenance Therapy, No Maintenance treatment ( Standard of Care) - Carcinoma in Situ, Transitional Cell Carcinoma | Phase 3 | Terminated | Endo USA Inc., a Keenova Therapeutics Company | 1 | 2011-05-01 | 2017-10-05 |
| AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer BCG vaccine, valrubicin, conventional surgery - Bladder Cancer | Phase 2 | Completed | Anthra Pharmaceuticals | 1998-11-01 | 2013-01-31 | |
| Chemotherapy in Treating Patients With Early-Stage Bladder Cancer valrubicin - Bladder Cancer | Phase 2 | Completed | Eastern Cooperative Oncology Group | 75 | 1998-09-01 | 2023-06-22 |
| Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer valrubicin, conventional surgery - Bladder Cancer | Phase 3 | Unknown | Anthra Pharmaceuticals | 300 | 1996-12-01 | 2013-11-06 |
| Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) Valrubicin, 800 mg - Carcinoma in Situ, Bladder Cancer | Phase 2 / Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 90 | 1993-11-01 | 2015-06-12 |
Urinary Bladder Neoplasms (6) · Carcinoma in Situ (3) · Carcinoma, Transitional Cell (3) · Neoplasms (3) · Adenoviridae Infections (1) · Neoplasms by Site (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Urinary Bladder Diseases (1) · Urogenital Neoplasms (1) · Urologic Diseases (1) · Urologic Neoplasms (1) · Virus Diseases (1)
Anthra Pharmaceuticals (2) · Endo USA Inc., a Keenova Therapeutics Company (2) · CG Oncology, Inc. (1) · Eastern Cooperative Oncology Group (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
United States (7) · Canada (1)
Alex W Yeung, MBBS (1) · Colin P. Dinney, MD (1) · Jeffrey M. Ignatoff, MD (1) · Peter R. Carroll, MD (1) · Philippe E Spiess, MD, MS, FACS, FRCS(C) (1) · Wade Sexton, M.D. (1)